Ketamine Korner: Edition 10

Ketamine Korner is a bi-weekly newsletter exploring advances in ketamine therapy, originally started by Mind Pain Relief Institute Co-Founder Dr. Rohit Aiyer. 

Each edition is republished with permission from Dr. Aiyer.

Latest Research Highlight:

Research Update: A growing body of research suggests that inflammatory processes may contribute to both treatment-resistant depression and certain chronic pain conditions.

A study published in Biological Psychiatry (Yang et al., 2015) observed reductions in pro-inflammatory cytokines, including interleukin-6 (IL-6), following ketamine administration, alongside improvements in depressive symptoms. These findings suggest a possible association between ketamine treatment and changes in inflammatory signaling, though the direction and consistency of this relationship vary across studies.

Additional work in Molecular Psychiatry (Abdallah et al., 2018) explored whether baseline inflammatory markers influence response to ketamine. The results suggest that inflammatory state may play a role in predicting treatment response, although this remains an area of ongoing investigation rather than a definitive clinical tool.

In the pain literature, conditions such as fibromyalgia and CRPS are associated with central sensitization and neuroinflammatory processes, which overlap with pathways implicated in mood disorders. Ketamine’s effects on glutamatergic signaling and synaptic plasticity may indirectly influence these systems.

Taken together, current evidence suggests that ketamine’s effects may extend beyond neurotransmission alone, potentially interacting with broader neurobiological systems, including those involved in stress and immune signaling.

A Brief History of Inflammation in Psychiatry and Pain:

From Separate Models to Overlap: Historically, depression and chronic pain were conceptualized as distinct conditions, treated within separate clinical frameworks.

Emergence of the Inflammatory Hypothesis: Over the past two decades, research has identified associations between elevated inflammatory markers and both depression and chronic pain, leading to the concept of inflammation as a contributing factor in certain patient populations.

Ketamine and Mechanistic Expansion: As ketamine’s rapid antidepressant effects were studied, attention shifted toward glutamatergic pathways, synaptic plasticity, and downstream signaling systems—including possible interactions with inflammatory processes.

Current Perspective: Inflammation is now considered one of several interconnected pathways that may contribute to both pain and mood disorders, rather than a single unifying cause.

Mythbuster:

Myth: Ketamine works purely through neurotransmitters and has no relationship to inflammation.

Reality:

• Some studies have observed changes in inflammatory markers following ketamine administration, though findings are not fully consistent.

• Inflammation may influence treatment response in certain patients, but this is not yet used routinely in clinical decision-making.

• Ketamine’s effects are best understood as multi-layered, involving glutamate signaling, synaptic plasticity, and broader neurobiological systems.

Rather than acting as a direct anti-inflammatory treatment, ketamine may influence multiple interacting systems that contribute to both pain and mood regulation.

Key Takeaway:

Ketamine’s clinical effects likely extend beyond a single mechanism. While its primary action remains tied to glutamatergic modulation and neuroplasticity, emerging research suggests it may also interact with systems involved in stress and inflammation.

At present, the relationship between ketamine and inflammatory processes is best understood as an evolving area of research, not a definitive explanation of its therapeutic effects.

As the science develops, integrating insights from psychiatry, pain medicine, and neuroimmunology may help refine how ketamine is used in complex, treatment-resistant conditions.

As the science evolves, so does our understanding of ketamine’s place in modern psychiatry and pain medicine. Staying informed helps us separate fact from myth and support thoughtful, evidence-based care.

Until next time, stay curious and engaged with the possibilities ahead.